Multi-substituted imidazolines and method of use thereof

Organic compounds -- part of the class 532-570 series – Organic compounds – Heterocyclic carbon compounds containing a hetero ring...

Reexamination Certificate

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

Reexamination Certificate

active

07858808

ABSTRACT:
A new class of imidazolines as 4-position acids or esters with very potent anti-inflammatory as well as antimicrobial activity is described. The synthesis of these imidazolines includes a multicomponent reaction applicable to a combinatorial synthetic approach. The combination of these two key characteristics provides an effective therapeutic drug in the treatment of septic shock as well as many other inflammatory (arthritis and asthma) and infectious disorders. The use of this novel class of non-steroidal agents as anti-inflammatory agents (for the treatment of asthma etc.), antibacterial agents and antiseptic agents is described. The compounds are also useful in the treatment of tumors (such as cancers). The imidazolines are potent inhibitors of the transcription factor NF-κB as well as potent activity against the Gram (+) bacteriumB. subtillusandB. cereuswith MIC values in the range of 50 μm/mL.

REFERENCES:
patent: 3354173 (1967-11-01), Godefroi et al.

LandOfFree

Say what you really think

Search LandOfFree.com for the USA inventors and patents. Rate them and share your experience with other people.

Rating

Multi-substituted imidazolines and method of use thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Multi-substituted imidazolines and method of use thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Multi-substituted imidazolines and method of use thereof will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFUS-PAI-O-4219146

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.